CN106459173A - 人源化可变淋巴细胞受体（vlr）及其相关组合物和用途 - Google Patents

人源化可变淋巴细胞受体（vlr）及其相关组合物和用途 Download PDF

Info

Publication number
CN106459173A
CN106459173A CN201580021759.0A CN201580021759A CN106459173A CN 106459173 A CN106459173 A CN 106459173A CN 201580021759 A CN201580021759 A CN 201580021759A CN 106459173 A CN106459173 A CN 106459173A
Authority
CN
China
Prior art keywords
leu
xaa
amino acid
asn
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580021759.0A
Other languages
English (en)
Chinese (zh)
Inventor
布兰特利·R·赫林
马克斯·戴尔·库珀
鲁道夫·埃尔哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CN106459173A publication Critical patent/CN106459173A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580021759.0A 2014-05-02 2015-04-30 人源化可变淋巴细胞受体（vlr）及其相关组合物和用途 Pending CN106459173A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987566P 2014-05-02 2014-05-02
US61/987,566 2014-05-02
PCT/US2015/028645 WO2015168469A1 (en) 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto

Publications (1)

Publication Number Publication Date
CN106459173A true CN106459173A (zh) 2017-02-22

Family

ID=54359347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580021759.0A Pending CN106459173A (zh) 2014-05-02 2015-04-30 人源化可变淋巴细胞受体（vlr）及其相关组合物和用途

Country Status (8)

Country Link
US (3) US10167330B2 (https=)
EP (1) EP3137496A4 (https=)
JP (1) JP2017514522A (https=)
KR (1) KR20160147787A (https=)
CN (1) CN106459173A (https=)
CA (1) CA2947429A1 (https=)
IL (1) IL248327A0 (https=)
WO (1) WO2015168469A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770255A (zh) * 2017-04-11 2020-02-07 印希彼有限公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
CN114867737A (zh) * 2019-11-12 2022-08-05 国家医疗保健研究所 用于潜伏型弓形虫病的新血清学标志物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用
SE1500434A1 (en) * 2015-10-29 2017-04-30 Theravac Pharmaceuticals Ab A novel fusion partner for highly efficient and safe vaccines
CN107365387B (zh) 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN106543278B (zh) 2016-12-06 2019-04-12 阿思科力(苏州)生物科技有限公司 融合蛋白Slit2D2(C386S)-HSA及其在治疗纤维化疾病中的应用
JP2020505472A (ja) * 2017-01-27 2020-02-20 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 自己免疫性糖尿病のための二官能性低分子ペプチド
US20200048321A1 (en) * 2017-03-24 2020-02-13 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
KR101972894B1 (ko) * 2017-05-18 2019-04-29 경상대학교산학협력단 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
US12077609B2 (en) 2018-12-21 2024-09-03 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
WO2020167735A1 (en) 2019-02-11 2020-08-20 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the blood brain barrier and methods of use
JP2024527977A (ja) * 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
CN114891799B (zh) * 2022-05-20 2024-10-11 宁波大学 中华绒螯蟹可变淋巴受体vlr2基因及其编码的蛋白和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083275A2 (en) * 2004-05-21 2006-08-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
CN103033617A (zh) * 2012-11-30 2013-04-10 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118777A (ja) * 1997-07-09 1999-01-26 Asahi Chem Ind Co Ltd 新規スリット様ポリペプチド
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US9127087B2 (en) 2008-12-01 2015-09-08 University Of Maryland, Baltimore High affinity recombinant sea lamprey antibodies selected by a Yeast Surface Display platform
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013078425A1 (en) 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083275A2 (en) * 2004-05-21 2006-08-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
CN103033617A (zh) * 2012-11-30 2013-04-10 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BYUNG WOO HAN ET AL: "Antigen recognition by variable lymphocyte receptors", 《SCIENCE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770255A (zh) * 2017-04-11 2020-02-07 印希彼有限公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
CN114867737A (zh) * 2019-11-12 2022-08-05 国家医疗保健研究所 用于潜伏型弓形虫病的新血清学标志物

Also Published As

Publication number Publication date
WO2015168469A1 (en) 2015-11-05
JP2017514522A (ja) 2017-06-08
US10167330B2 (en) 2019-01-01
US20190202887A1 (en) 2019-07-04
US20200308247A1 (en) 2020-10-01
KR20160147787A (ko) 2016-12-23
EP3137496A4 (en) 2017-10-11
EP3137496A1 (en) 2017-03-08
US20170081385A1 (en) 2017-03-23
CA2947429A1 (en) 2015-11-05
IL248327A0 (en) 2016-11-30
US11384134B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
US11384134B2 (en) Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
US11136369B2 (en) Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
EP3253795B1 (en) Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP2021520198A (ja) Ｔ細胞受容体およびそれを発現する操作された細胞
CN110177808A (zh) 针对axl或ror2的嵌合抗原受体及其使用方法
JP2019193652A (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CA2430528A1 (en) Hybrid antibodies
CN111448314B (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
CN110225770A (zh) 结合cd8a的纤连蛋白iii型结构域
CN111247429B (zh) 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
JP2021508246A (ja) 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
CN115702163A (zh) 异二聚体蛋白质
CN113614103A (zh) 不直接向其附着的细胞传导信号的非天然nkg2d受体
JP2020530766A (ja) フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
CN104558181A (zh) 靶向b淋巴瘤细胞的人源单链抗体
US20220411472A1 (en) Self-assembling circular tandem repeat proteins with increased stability
EP4671276A1 (en) ANTIBODY BANK CONTAINING A COMMON LIGHT CHAIN, ITS PREPARATION METHOD AND ITS USE
WO2022104424A1 (en) Chimeric antigen receptor t cell and method
WO2025059589A1 (en) Immune cell engaging molecules
CN121294179A (zh) 一种工程化细胞
KR20250174648A (ko) 이종이량체 항체, 치료적 적용에서의 용도, 및 이와 관련된 조성물
CN104558180A (zh) 靶向t淋巴细胞的人源单链抗体
HK40061399A (en) Non-natural nkg2d receptors that do not directly signal the cells to which they are attached
HK40019803B (zh) 改进的抗原结合受体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222